2018 American Transplant Congress
Alemtuzumab Induction as a Mediator of Nonadherence in Renal Transplantation
University of Toledo College of Medicine, Toledo, OH.
Introduction: “Non-adherent” (NA) is defined as chronic follow-up absenteeism or medication nonadherence. We aimed to determine whether the single-dosing schedule of Alemtuzumab (Ale) may limit…2018 American Transplant Congress
Impact of Steroid Maintenance on the Outcomes of HLA-DR Mismatch Kidney Transplantation
Allegheny General Hospital, Pittsburgh, PA.
In kidney transplantation, donor-recipient HLA-DR mismatch poses high immunologic risk and is associated with inferior outcomes. We aimed to explore the impact of enhanced immunosuppression…2018 American Transplant Congress
The Infusion with a Difference: Patient Experiences with Belatacept
Yale University, New Haven, CT.
Introduction: The results of the BENEFIT trial led to the FDA approval of the novel anti-rejection agent belatacept (bela) in 2011. In addition to its…2018 American Transplant Congress
A Six-Month, Prospective, Single-Center, Pilot Study to Determine the Pharmacokinetics and Effectiveness of Immunosuppressant Regimens in Liver Transplantation Patients Receiving Twice-Daily Tacrolimus and Everolimus (TAC + EVR BID) Regimen Converted to Once-Daily Tacrolimus and Everolimus (TAC + EVR QD) Regimen – A Priliminary Report
Adherence to immunosuppressant regimen is crucial for graft survival and usually inversely related to the dose frequency. Similar efficacy and safety profile has been approved…2018 American Transplant Congress
Characterization of Mesenchymal Stem Cell Phenotype and Its Immunomodulatory Effects during Allo-Specific T Cell Immune-Responses
Department of Surgery, Duke University Medical Center, Durham, NC.
Mesenchymal stem cells (MSCs) have been suggested play an important role in modulating cell-mediated immunity. In the setting of transplantation, allogeneic MSCs could mediate suppressive…2018 American Transplant Congress
The ATHENA Study: 12 Months Safety and Efficacy Data from Everolimus Combined with Tacrolimus or Cyclosporine Compared to a Standard Tacrolimus-Mycophenolate Regimen in De Novo Kidney Transplant Patients
1Athena Study Group, Germany; 2Athena Study Group, France; 3Novartis, Pharma, Germany.
The ATHENA study was set up to compare efficacy and safety of everolimus [EVR] combined with tacrolimus [TAC] or cyclosporine A [CyA] vs. a mycophenolic…2018 American Transplant Congress
Metabolic Therapy as a Platform for CTLA4Ig Costimulation Blockade in Preventing Allograft Rejection
The backbone of current immunosuppression regimens remains calcineurin inhibitors (CNI) in association with steroids, mycophenolate mofetil or mTOR inhibitors. However, their long-term administration is associated…2018 American Transplant Congress
Clinical Impact of Denovo or Recurrent Donor Specific Antibodies in the First Year Post Kidney Transplant in Patients on Early Steroid Withdrawal Immunosupression Regimen
Division of Renal Disease and Hypertension, Indiana University Health, Indianapolis, IN.
Background: Immunologic risk monitoring of recipients of kidney transplant(Tx) using donor specific antibodies (DSA) has become a standard practice in most Tx centers in the…2018 American Transplant Congress
Association of CYP3A5*3*6*7 Metabolic Composites to Tacrolimus Pharmacokinetics in African American and Caucasian Renal Transplant Recipients
Background: Interpatient variability in tacrolimus pharmacokinetics(PK) is due primarily to metabolism by cytochrome P-450 3A5(CYP3A5) isoenzymes. African Americans(AA) require higher tacrolimus doses to achieve comparable…2018 American Transplant Congress
Hyperkalemia in the Early Post Renal Transplant Period
Hyperkalemia is a recognized and potentially life threatening complication post renal transplantation. Aside from delayed graft function, the most frequent culprit identified is pharmacotherapy. Many…
- « Previous Page
- 1
- …
- 79
- 80
- 81
- 82
- 83
- …
- 138
- Next Page »